Kaleido Biosciences up on launching second study of potential COVID-19 drug

Kaleido Biosciences

23/07/2020 13:52

** Drug developer's shares  KLDO.O  rise 9.3% to $6.80
premarket
    ** Co starts controlled clinical study testing its
experimental treatment, KB109, along with self-care practices
being followed by outpatients with moderate COVID-19 disease
 urn:newsml:reuters.com:*:nGNX7ptbvJ
    ** Fifty participants will either receive Supportive
Self-Care (SSC) or SSC plus KB109 for two weeks followed by a
three-week observation period; Participants will be evaluated
for safety, physiologic effects and gut microbiota structure and
function
    ** Data from study, which KLDO is conducting with
Massachusetts General Hospital, is expected in Q1 2021
    ** Earlier, KLDO launched study assessing KB109 in 350
outpatients with mild-to-moderate COVID-19 disease
    ** KLDO stock had risen ~30% this year, up to last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))